Schizophrenia and comorbid metabolic disorders

Journal of Clinical Psychiatry

Volumn 66, Issue SUPPL. 6, 2005, Pages 11-20

  Henderson, David C ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b Freedom Trail Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANOREXIGENIC AGENT; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BIGUANIDE; CLOZAPINE; DIKETONE; DOPAMINE 2 RECEPTOR; FIBRIC ACID DERIVATIVE; FISH OIL; HALOPERIDOL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LITHIUM; LOW DENSITY LIPOPROTEIN CHOLESTEROL; NEUROLEPTIC AGENT; NICOTINIC ACID; OLANZAPINE; PHENOTHIAZINE DERIVATIVE; PROLACTIN; QUETIAPINE; RISPERIDONE; SEROTONIN 2C ANTAGONIST; SEROTONIN 2C RECEPTOR; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; VALPROIC ACID; ZIPRASIDONE;

BODY MASS; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMORBIDITY; DIABETES MELLITUS; DIABETIC KETOACIDOSIS; DRUG EFFECT; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DYSLIPIDEMIA; EXERCISE; GLUCOSE BLOOD LEVEL; HEALTH CARE COST; HEALTH EDUCATION; HEALTH SURVEY; HUMAN; HYPERGLYCEMIA; HYPERLIPIDEMIA; HYPERPROLACTINEMIA; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIFESTYLE; LIPID BLOOD LEVEL; META ANALYSIS; METABOLIC DISORDER; METABOLIC SYNDROME X; NONHUMAN; NUTRITION; OBESITY; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SEXUAL DYSFUNCTION; SIDE EFFECT; SMOKING CESSATION; SYSTEMATIC REVIEW; WEIGHT GAIN;

ANTIPSYCHOTIC AGENTS; COMORBIDITY; GLUCOSE METABOLISM DISORDERS; HUMANS; HYPERLIPIDEMIAS; HYPERPROLACTINEMIA; METABOLIC DISEASES; OBESITY; RISK FACTORS; SCHIZOPHRENIA;

EID: 24144481492     PISSN: 01606689     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. World Health Organization. Obesity and overweight. Available at: http:// www.who.int/dietphysicalactivity/publications/facts/obesity/en/. Accessed May 7, 2004
2. Wild S, Roglic G, Green A, et al. Global prevalence of diabetes: estimates for the year 2000 and projections for 2030. Diabetes Care 2004;27: 1047-1053
3. American Diabetes Association, American Psychiatric Association, American Association of Clinical Endocrinologists, et al. Consensus development conference on antipsychotic drugs and obesity and diabetes. J Clin Psychiatry 2004;65:267-272
4. Kapur S, Zipursky R, Jones C, et al. Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 2000;157:514-520
5. Halbreich U, Kinon BJ, Gilmore JA, et al. Elevated prolactin levels in patients with schizophrenia: mechanisms and related adverse effects. Psychoneuroendocrinology 2003;28(suppl 1):53-67
6. Compton MT, Miller AH. Antipsychotic-induced hyperprolactinemia and sexual dysfunction. Psychopharmacol Bull 2002;36:143-164
7. Kapur S, Zipursky RB, Remington G, et al. 5-HT2 and D2 receptor occupancy of olanzapine in schizophrenia: a PET investigation. Am J Psychiatry 1998;155:921-928
8. Kapur S, Zipursky RB, Remington G. Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 1999;156:286-293
9. Nordstrom AL, Farde L, Nyberg S, et al. D1, D2, and 5-HT2 receptor occupancy in relation to clozapine serum concentration: a PET study of schizophrenic patients. Am J Psychiatry 1995;152:1444-1449
10. 2 receptor occupancy. Arch Gen Psychiatry 2000;57:553-559
11. Arvanitis LA, Miller BG. Multiple fixed doses of "Seroquel" (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997;42:233-246
12. Halbreich U, Kahn LS. Hormonal aspects of schizophrenias: an overview. Psychoneuroendocrinology 2003;28:1-16
13. Wieck A, Akande B, Haddad P, et al. Bone mineral density (BMD) in premenopausal women with antipsychotic-induced amenorrhea or oligomenorrhea. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
14. Knegtering H, van der Moolen AE, Castelein S, et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology 2003;28:109-123
15. Knegtering R, Castelein S, Bous H, et al. A randomized open-label study of the impact of quetiapine versus risperidone on sexual functioning. J Clin Psychopharmacol 2004;24:56-61
16. Mokdad AH, Ford ES, Bowman BA, et al. Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001. JAMA 2003;289:76-79
17. Meyer JM. Effects of atypical antipsychotics on weight and serum lipid levels. J Clin Psychiatry 2001;62(suppl 27):27-34
18. Allison DB, Fontaine KR, Heo M, et al. The distribution of body mass index among individuals with and without schizophrenia. J Clin Psychiatry 1999;60:215-220
19. Allison DB, Casey DE. Antipsychotic-induced weight gain: a review of the literature. J Clin Psychiatry 2001;62(suppl 7):22-31
20. Aronne LJ. Epidemiology, morbidity, and treatment of overweight and obesity. J Clin Psychiatry 2001;62(suppl 23):13-22
21. Basson BR, Kinon BJ, Taylor CC, et al. Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone. J Clin Psychiatry 2001;62:231-238
22. Hagg S, Soderberg S, Ahren B, et al. Leptin concentrations are increased in subjects treated with clozapine or conventional antipsychotics. J Clin Psychiatry 2001;62:843-848
23. McIntyre RS, Mancini DA, Basile VS. Mechanisms of antipsychotic-induced weight gain. J Clin Psychiatry 2001;62(suppl 23):23-29
24. Wetterling T. Bodyweight gain with atypical antipsychotics: a comparative review. Drug Saf 2001;24:59-73
25. Nonogaki K, Strack AM, Dallman MF, et al. Leptin-independent hyperphagia and type 2 diabetes in mice with a mutated serotonin 5-HT2C receptor gene. Nat Med 1998;4:1152-1156
26. Goldstein J, Zhong K. Tolerance to somnolence with quetiapine: preclinical mechanisms and clinical evidence. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
27. George TP, Sernyak MJ, Ziedonis DM, et al. Effects of clozapine on smoking in chronic schizophrenic outpatients. J Clin Psychiatry 1995; 56:344-346
28. George TP, Ziedonis DM, Feingold A, et al. Nicotine transdermal patch and atypical antipsychotic medications for smoking cessation in schizophrenia. Am J Psychiatry 2000;157:1835-1842
29. Lasser RA, Mao L, Gharabawi G. Smokers and nonsmokers equally affected by olanzapine-induced weight gain: metabolic implications. Schizophr Res 2004;66:163-167
30. Zhang ZJ, Yao ZJ, Liu W, et al. Effects of antipsychotics on fat deposition and changes in leptin and insulin levels: magnetic resonance imaging study of previously untreated people with schizophrenia. Br J Psychiatry 2004;184:58-62
31. Kinon BJ, Basson BR, Gilmore JA, et al. Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia. J Clin Psychiatry 2001;62:92-100
32. Vanina Y, Podolskaya A, Sedky K, et al. Body weight changes associated with psychopharmacology. Psychiatr Serv 2002;53:842-847
33. Allison DB, Mentore JL, Heo M, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am J Psychiatry 1999;156: 1686-1696
34. Keck PE Jr, Marcus R, Tourkodimitris S, et al. A placebo-controlled, double-blind study of the efficacy and safety of aripiprazole in patients with acute bipolar mania. Am J Psychiatry 2003;160:1651-1658
35. Brecher M, Rak IW, Melvin K, et al. The long-term effect of quetiapine ('Seroquel') monotherapy on weight in patients with schizophrenia. Int J Psychiatry Clin Pract 2000;4:287-291
36. Henderson DC, Cagliero E, Gray C, et al. Clozapine, diabetes mellitus, weight gain, and lipid abnormalities: a five-year naturalistic study. Am J Psychiatry 2000;157:975-981
37. Evans A, Bonetto GG, Toledo D, et al. Patterns of antipsychotic- associated weight change: 1 year results from the IC-SOHO study. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
38. Gupta S, Masand PS, Virk S, et al. Weight decline in patients switching from olanzapine to quetiapine. Schizophr Res 2004;70:57-62
39. Reinstein M, Sirotovskaya L, Jones L, et al. Effect of clozapine-quetiapine combination therapy on weight and glycaemic control. Clin Drug Invest 1999;18:99-104
40. Fontaine KR, Heo M, Harrigan EP, et al. Estimating the consequences of antipsychotic-induced weight gain on health and mortality rate. Psychiatry Res 2001;101:277-288
41. Wolf AM, Colditz GA. Current estimates of the economic cost of obesity in the United States. Obes Res 1998;6:97-106
42. Finkelstein E, Fiebelkorn I, Wang G. National medical spending attributable to overweight and obesity: how much, and who's paying? Health Aff (Millwood) 2003;Jan-Jun Suppl:W3-219-226
43. American Heart Association. Heart Disease and Stroke Statistics: 2004 Update. Dallas, Tex: American Heart Association; 2003:1-50
44. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP). JAMA 2001;285:2486-2497
45. Garyfallos G, Dimelis D, Kouniakis P, et al. Olanzapine versus risperidone: weight gain and elevation of serum triglyceride levels. Eur Psychiatry 2003;18:320-321
46. Atmaca M, Kuloglu M, Tezcan E, et al. Serum leptin and triglyceride levels in patients on treatment with atypical antipsychotics. J Clin Psychiatry 2003;64:598-604
47. Kelly DL, Kreyenbuhl J, Love RC, et al. Six-month review of weight and metabolic parameters in patients receiving clozapine, risperidone, olanzapine, or quetiapine [letter]. J Clin Psychiatry 2003;64:1133-1134
48. Nasrallah H, Loebel A, Murray S. Lipid profile pre- and post-treatment in ziprasidone clinical trials. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
49. Ghaeli P, Dufresne RL. Elevated serum triglycerides with clozapine resolved with risperidone in four patients. Pharmacotherapy 1999;19: 1099-1101
50. Ghaeli P, Dufresne RL. Serum triglyceride levels in patients treated with clozapine. Am J Health Syst Pharm 1996;53:2079-2081
51. Sheitman BB, Bird PM, Binz W, et al. Olanzapine-induced elevation of plasma triglyceride levels [letter]. Am J Psychiatry 1999;156:1471-1472
52. Osser DN, Najarian DM, Dufresne RL. Olanzapine increases weight and serum triglyceride levels. J Clin Psychiatry 1999;60:767-770
53. American Diabetes Association. Dyslipidemia management in adults with diabetes. Diabetes Care 2004;27(suppl 1):S68-S71
54. Lebovitz HE. Diagnosis, classification, and pathogenesis of diabetes mellitus. J Clin Psychiatry 2001;62(suppl 27):5-9
55. American Diabetes Association. Standards of medical care in diabetes. Diabetes Care 2004;27(suppl 1):S15-S35
56. Haupt DW, Newcomer JW. Hyperglycemia and antipsychotic medications. J Clin Psychiatry 2001;62(suppl 27):15-26
57. Lindenmayer J-P, Nathan A-M, Smith RC. Hyperglycemia associated with the use of atypical antipsychotics. J Clin Psychiatry 2001;62 (suppl 23):30-38
58. Regenold WT, Thapar RK, Marano C, et al. Increased prevalence of type 2 diabetes mellitus among psychiatric inpatients with bipolar I affective and schizoaffective disorders independent of psychotropic drug use. J Affect Disord 2002;70:19-26
59. Gianfrancesco F, Wang R. A comprehensive retrospective study of associations between diabetes and treatment with risperidone, olanzapine, quetiapine, and conventional antipsychotics. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
60. Henderson DC. Atypical antipsychotic-induced diabetes mellitus: how strong is the evidence? CNS Drugs 2002;16:77-89
61. Jin H, Meyer JM, Jeste DV. Phenomenology of and risk factors for new-onset diabetes mellitus and diabetic ketoacidosis associated with atypical antipsychotics: an analysis of 45 published cases. Ann Clin Psychiatry 2002;14:59-64
62. Dwyer DS, Liu Y, Bradley RJ. Dopamine receptor antagonists modulate glucose uptake in rat pheochromocytoma (PC12) cells. Neurosci Lett 1999;274:151-154
63. Liebzeit KA, Markowitz JS, Caley CF. New onset diabetes and atypical antipsychotics. Eur Neuropsychopharmacol 2001;11:25-32
64. Newcomer JW, Haupt DW, Fucetola R, et al. Abnormalities in glucose regulation during antipsychotic treatment of schizophrenia. Arch Gen Psychiatry 2002;59:337-345
65. Avram AM, Patel V, Taylor HC, et al. Euglycemic clamp study in clozapine-induced diabetic ketoacidosis. Ann Pharmacother 2001; 35:1381-1387
66. Glick ID, Fryburg D, O'Sullivan R, et al. Ziprasidone's benefits versus olanzapine on weight and insulin resistance. Presented at the 154th annual meeting of the American Psychiatric Association; May 5-10, 2001; New Orleans, La
67. Henderson DC, Cagliero E, Copeland PM, et al. Glucose metabolism in patients with schizophrenia treated with atypical antipsychotic agents: a frequently sampled intravenous glucose tolerance test and minimal model analysis. Arch Gen Psychiatry 2005;62:19-28
68. Littrell K, Petty R, Hilligoss N, et al. The effect of aripiprazole on insulin resistance in schizophrenia. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
69. Abilify (aripiprazole). Full prescribing information. Princeton, NJ: Bristol-Myers Squibb Company; 2004
70. Seroquel (quetiapine fumarate). Full prescribing information. Wilmington, Del: AstraZeneca Pharmaceuticals LP; 2004
71. Risperdal (risperidone). Full prescribing information. Titusville, NJ: Janssen Pharmaceutica; 2003
72. Clozaril (clozapine). Full prescribing information. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2003
73. Zyprexa (olanzapine). Full prescribing information. Indianapolis, Ind: Eli Lilly and Company; 2004
74. Geodon (ziprasidone). Full prescribing information. New York, NY: Pfizer Inc; 2004
75. Henderson DC. Clinical experience with insulin resistance, diabetic ketoacidosis, and type 2 diabetes mellitus in patients treated with atypical antipsychotic agents. J Clin Psychiatry 2001;62 (suppl 27):10-14
76. Haffner SM, Lehto S, Ronnemaa T, et al. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 1998;339:229-234
77. Messier C. Glucose improvement of memory: a review. Eur J Pharmacol 2004;490:33-57
78. Ford ES, Giles WH, Dietz WH. Prevalence of the metabolic syndrome among US adults: findings from the third National Health and Nutrition Examination Survey. JAMA 2002;287:356-359
79. Heiskanen T, Niskanen L, Lyytikäinen R, et al. Metabolic syndrome in patients with schizophrenia. J Clin Psychiatry 2003;64:575-579
80. Pandina G, Greenspan A, Bossie C, et al. The metabolic syndrome in patients with schizophrenia. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
81. Casey D, L'Italien G, Cislo P. Comparative one-year incidence/worsening of metabolic syndrome among patients treated with olanzapine vs aripiprazole. Presented at the 157th annual meeting of the American Psychiatric Association; May 1-6, 2004; New York, NY
82. Ryan MC, Thakore JH. Physical consequences of schizophrenia and its treatment: the metabolic syndrome. Life Sci 2002;71:239-257
83. Henderson D. Diabetes mellitus and other metabolic disturbances induced by atypical antipsychotic agents. Curr Diab Rep 2002;2:135-140
84. Meltzer HY. Putting metabolic side effects into perspective: risks versus benefits of atypical antipsychotics. J Clin Psychiatry 2001; 62(suppl 27):35-39